Literature DB >> 9457201

Primary breast abnormalities: selective pixel sampling on dynamic gadolinium-enhanced MR images.

S Mussurakis1, P Gibbs, A Horsman.   

Abstract

PURPOSE: To evaluate a region-of-interest (ROI) analytic method that involves selective sampling of pixels within predetermined ranges of contrast material enhancement values ("thresholding") on magnetic resonance (MR) images of primary breast abnormalities.
MATERIALS AND METHODS: Dynamic gadolinium-enhanced MR images were obtained in 105 women. ROIs were drawn to outline the full extent of lesions. Relative signal intensity increase was determined on a pixel-by-pixel basis on 1- and 2-minute postcontrast images, as was the maximum relative signal intensity increase. Thresholding was used to analyze each ROI, with the upper boundary defined by the highest pixel value and lower boundaries of 0%-100%.
RESULTS: Seventy-one invasive carcinomas and 37 benign lesions were analyzed. Narrower thresholding (i.e., larger percentage) resulted in an increase in all enhancement ratios (P < .0005). The enhancement ratio on 1-minute postcontrast images differed between benign lesions and carcinomas (P < .0005), but there were no significant differences in 2-minute and maximum ratios. Mean enhancement differences between benign and malignant lesions increased with narrower thresholding, but variability also increased linearly. Results of receiver operating characteristic analysis showed that thresholding did not affect the diagnostic usefulness of enhancement ratios.
CONCLUSION: Contrary to current opinion, selective sampling of the most enhancing areas of breast abnormalities may not provide any diagnostic advantage over the use of easily drawn, lesion-encompassing ROIs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457201     DOI: 10.1148/radiology.206.2.9457201

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

1.  Dynamic breast MR imaging: is parametric mapping superior to image subtraction in lesion detection?

Authors:  Kathinka D Kurz; Hans-Jörg Wittsack; Reinhart Willers; Dirk Blondin; Ulrich Mödder; Andreas Saleh
Journal:  Eur Radiol       Date:  2007-06-16       Impact factor: 5.315

2.  Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.

Authors:  Jayant Narang; Rajan Jain; Ali Syed Arbab; Tom Mikkelsen; Lisa Scarpace; Mark L Rosenblum; David Hearshen; Abbas Babajani-Feremi
Journal:  Neuro Oncol       Date:  2011-07-29       Impact factor: 12.300

3.  Effect of the enhancement threshold on the computer-aided detection of breast cancer using MRI.

Authors:  Jacob E D Levman; Petrina Causer; Ellen Warner; Anne L Martel
Journal:  Acad Radiol       Date:  2009-06-09       Impact factor: 3.173

4.  Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples.

Authors:  Thomas E Yankeelov; John C Gore
Journal:  Curr Med Imaging Rev       Date:  2009-05-01

5.  Improved discrimination of breast lesions using selective sampling of segmented MR images.

Authors:  Bashar Issa
Journal:  MAGMA       Date:  2006-02-08       Impact factor: 2.310

Review 6.  Perfusion MRI: the five most frequently asked clinical questions.

Authors:  Marco Essig; Thanh Binh Nguyen; Mark S Shiroishi; Marc Saake; James M Provenzale; David S Enterline; Nicoletta Anzalone; Arnd Dörfler; Àlex Rovira; Max Wintermark; Meng Law
Journal:  AJR Am J Roentgenol       Date:  2013-09       Impact factor: 3.959

Review 7.  Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review.

Authors:  Xiangyu Yang; Michael V Knopp
Journal:  J Biomed Biotechnol       Date:  2011-04-26

8.  Differentiation of breast cancer from fibroadenoma with dual-echo dynamic contrast-enhanced MRI.

Authors:  Shiwei Wang; Zachary Delproposto; Haoyu Wang; Xuewei Ding; Conghua Ji; Bei Wang; Maosheng Xu
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.